Asthma - KOL Insight

Why do KOLs say GSK's next-generation anti-IL5 mAb depemokimab has the potential to impact the uptake of the established anti-IL5 therapies? What factors are hindering the initial uptake of AstraZeneca/Amgen's novel anti-TSLP mAb, Tezspire, and what could shape its future? Why are KOLs positive about the value of Sanofi/Regeneron's Dupixent in paediatric therapy? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (10)

Treatment algorithm

Research objectives (9)

Biologic therapies (43)

• Approved therapies (34)
  • Anti-IL5 therapies: Nucala (mepolizumab; GSK) and Fasenra (benralizumab; AstraZeneca) (8)
  • Anti-IL4/IL13 therapies: Dupixent (dupilumab; Regeneron/Sanofi) (12)
  • Anti-TSLP therapies: Tezspire (tezepelumab; Amgen/AstraZeneca) (14)
• Pipeline therapies (9)
  • Anti-IL5 therapies: depemokimab (GSK3511294; GSK) (9)

ICS/LABA/LAMA triple combination therapies (18)

• Approved therapies (8)
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; GSK), Enerzair Breezhaler (glycopyrronium/indacaterol/mometasone; Novartis) and Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi) (8)
• Pipeline therapies (10)
  • Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrronium; AstraZeneca) (10)

Dual fixed-combination therapies (21)

• Approved therapies (11)
  • Airsupra (salbutamol [albuterol]/budesonide; AstraZeneca/Avillion) (11)
• Pipeline therapies (10)
  • TEV-56248 (albuterol sulfate/fluticasone propionate; Teva) (10)

Other mechanisms of action (11)

• Pipeline therapies (11)
  • Dexpramipexole (Areteia Therapeutics) (11)

Future treatment paradigm (9)

• Key insights summary (9)

Appendix (4)

• KOL details (4)
  • KOLs from the USA (1)
  • KOLs from Europe (2)